New molecular subtypes of non-small cell lung cancer and the possibilities of their treatment
The tactics of treatment of the pulmonary adenocarcinoma is based on the identification of molecular genetic disorders. Over the past 10 years, a number of subtypes of this disease associated with various disorders have been identified. Activating BRAF gene mutations determine the pathogenesis of 1-4% of cases of pulmonary adenocarcinoma. The presence of these molecular disorders correlates with history of smoking. The use of BRAF inhibitors in combination with MEK inhibitors in this group of patients makes it possible to achieve a clinical effect in 75% of patients and 13-15 months without progression of the disease. Development of the optimal algorithm for screening of glandular lung tumors, including for the presence of BRAF mutations, will significantly improve the results of drug therapy for this group of patients.